Idelalisib Terminated Phase 1 Trials for Chronic Lymphocytic Leukaemia (CLL) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02538614Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia